- NEW DRUGS: A DOSE OF REALITY.
The Press Too Often Plays Up the Positive Late last year NBC began trumpeting the virtues of a new "superaspirin," the drug Celebrex, which is jointly marketed by G.D. Searle and Pfizer Inc. and would soon become the fastest-selling new drug ever. On December 1, the Nightly News reported that ......
- The Physician/Investigator's Obligation to Patients Participating in Research: The Case of Placebo Controlled Trials
HEADNOTE This article addresses medical negligence as a cause of action for harm to a research participant occasioned by withholding established, effective therapy in the placebo arm of a clinical trial, and the insufficiency of consent as a defense to such a claim. Some authors argue that the ethics of ......
- A call to action: Patients' access to clinical trials / Responses
The National Cancer Institute demonstrated its new Cancer Clinical Trials Education Program (CCTEP) at the American Association of Social Workers annual meeting in San Diego, California, in May 1998. The goal was to develop a cadre of social workers who could facilitate community outreach and health professional training using CCTEP....
- Successful ways to increase retention in a longitudinal study of lead-exposed children
Much has been written about low retention rates in longitudinal studies of children (Bender, Ilke, DuHamel, & Tinkelman, 1997; Hartsough, Babinski, & Lambert, 1996). Although no reports on retention rates in studies of lead-exposed children were found, other clinical trial studies reported varied retention rates. In a review of clinical ......
- Financial conflict of interest: An unresolved ethical frontier
Financial conflict of interest has become one of the most contentious issues in medicine today. Several decades ago studies disclosed that physicians who had investments in medical facilities were referring patients for more tests and procedures than physicians who had no such investments. More recently, physicians who forego expensive tests ......
- NJ PATIENTS, HOSPITALS AND DRUG COMPANIES BRING NEW MEDICINES TO MARKET THROUGH CLINICAL TRIALS
New Jersey clinical researchers are conducting more than 900 clinical trials of new and existing medicines in the state's hospitals, clinics and doctors' offices, according to the National Institutes of Health's (NIH) database.
- Hired Education
HEADNOTE A hidden culprit in the drug scandals: the increasingly corporatized university. M. MICHAEL WOLFE, A GASTROENTEROLOGIST at Boston University, admits he was duped by the Pharmacia Corporation, the manufacturer of the blockbuster arthritis drug Celebrex. (In 2003, the company was purchased by Pfizer.) In the summer of 2000, The ......